A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC).

ADI-270 - Adicet Bio

IMC001 - Immunofoco

https://meetings.asco.org/abstracts-presentations/252355/

Sumanta Pal; Benjamin Garmezy; Helen Budworth; Xiaoyan Du; Shon Green; Kevin Nishimoto; Jackie Kennedy-Wilde; Blake Aftab; Julia Maltzman; Gregory Vosganian; Brian Rini

Apr 23, 2025